Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10
HOS-088526 · Präparat HOS-083663
9
these medicinal products is necessary then extra care should be taken in monitoring renal function and
haematological parameters and, if required, the dosage of one or more agents should be reduced.
Limited data from clinical trials do not indicate a significantly increased risk of adverse reactions to
zidovudine with cotrimoxazole (see interaction information above relating to lamivudine and co-
trimoxazole), aerosolised pentamidine, pyrimethamine and acyclovir at doses used in prophylaxis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pentamidine (HOS-085605) pyrimethamine (HOS-088523) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 4e59e050f2a95aad8dec8d248556e0a7bfbe51e5cf26df584ad728dedbcfc250 · Zeichen 11873–12372 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090627 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6798–7049 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090690 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6745–6996 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-108574 · Präparat HOS-093047
Limited data from clinical trials do not indicate a significantly increased risk of adverse reactions to
zidovudine with cotrimoxazole (see interaction information above relating to lamivudine and co-
trimoxazole), aerosolised pentamidine, pyrimethamine and acyclovir at doses used in prophylaxis.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pentamidine (HOS-085605) pyrimethamine (HOS-088523) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 65108b49254b74ed80c34a93ee6d8dba7da3551e36dae3b5a082c3e422d1a31d · Zeichen 16948–17245 im Abschnitt
Wechselwirkungen · Evoltra
Evoltra 1 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 6–7
HOS-114437 · Präparat HOS-094089
6
Clofarabine is predominately excreted via the kidneys. Thus, the concomitant use of medicinal
products that have been associated with renal toxicity and those eliminated by tubular secretion such
as NSAIDs, amphotericin B, methotrexate, aminosides, organoplatines, foscarnet, pentamidine,
cyclosporin, tacrolimus, acyclovir and valganciclovir, should be avoided particularly during the 5 day
clofarabine administration period (see sections 4.4, 4.8 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) amphotericin B (HOS-109312) valganciclovir (HOS-085195) tacrolimus (HOS-085202) pentamidine (HOS-085605) acyclovir (HOS-088527) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-19T13:13:00Z · SHA-256 b6c4c8e2a08241633a344425bddf0c7c67b8e36cf88774f3228bedc236be1d69 · Passage 2979f48cbf11d4193497926b6e1aff778bd8f1c56ed70e51b47c44c6ee1eb4f6 · Zeichen 780–1241 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-116792 · Präparat HOS-094481
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit
blood trough concentrations and juice.
increase the risk of serious adverse
reactions (e.g., neurotoxicity, QT
prolongation) [see section 4.4].
Ciclosporin May increase tacrolimus whole The simultaneous use of
blood trough concentrations. In ciclosporin and tacrolimus
addition, synergistic/additive should be avoided [see
nephrotoxic effects can occur. section 4.4].
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus
nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have
effects: nephrotoxic effects should be
aminoglycosides, gyrase avoided. When co-
inhibitors, vancomycin, administration cannot be
sulfamethoxazole + avoided, monitor renal
trimethoprim, NSAIDs, function and other side effects
ganciclovir, acyclovir, and adjust tacrolimus dose if
amphotericin B, ibuprofen, needed.
cidofovir, foscarnet
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage b0395308050c5d9d3dab6530a2530819d6fdce6a20dc173d21940107d84f6ae3 · Zeichen 1941–3853 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Methylthioninium chloride Proveblue
Methylthioninium chloride Proveblue 5 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-213660 · Präparat HOS-155158
Methylthioninium chloride is a potent inhibitor of the transporters OCT2, MATE1 and MATE2-K. The
clinical consequences of the inhibition are not known. The administration of methylthioninium chloride
Proveblue has the potential to transiently increase the exposure of drugs primarily cleared by renal
transport involving the OCT2/MATE pathway, including cimetidine, metformin and acyclovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cimetidine (HOS-085835) acyclovir (HOS-088527) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-19T17:19:00Z · SHA-256 19c53bf82f55a8d25e4c6a9ce5fce20575d1af796cef659dc721231268971317 · Passage c928fa879e905932068e5503a53486761c143e48d500985f4ad5ce802b0148c1 · Zeichen 1429–1819 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-139809 · Präparat HOS-098408
10
Concomitant Effect on concentration† Recommendations concerning co-
medicinal product mean ratio (90% confidence administration with letermovir
interval) for AUC, Cmax
(likely mechanism of action)
Antivirals
acyclovir‡ ↔ acyclovir No dose adjustment required.
(400 mg single AUC 1.02 (0.87, 1.2)
dose)/ letermovir Cmax 0.82 (0.71, 0.93)
(480 mg daily)
valacyclovir Interaction not studied. No dose adjustment required.
Expected:
↔ valacyclovir
Herbal products
St. John’s wort Interaction not studied. St. John’s wort may decrease plasma
(Hypericum Expected: concentrations of letermovir.
perforatum) ↓ letermovir Co-administration of letermovir and St.
John’s wort is contraindicated.
(P-gp/UGT induction)
HIV medicinal products
efavirenz Interaction not studied. Efavirenz may decrease plasma
Expected: concentrations of letermovir.
↓ letermovir Co-administration of letermovir and
(P-gp/UGT induction) efavirenz is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valacyclovir (HOS-139811) efavirenz (HOS-087947) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 074b4fd3c9bd818aa4a77c31058f6297f3bf956f58dc7164720b108fc2d09d6d · Zeichen 16483–17932 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 43
HOS-139879 · Präparat HOS-098408
(Sum of OATP1B1/3 and/or
P-gp inhibition and P-gp/UGT
induction)
(600 mg once daily ↓ letermovir
PO (24 hours after AUC 0.15 (0.13, 0.17)
rifampicin))§/ Cmax 0.27 (0.22, 0.31)
letermovir (480 mg C24 0.09(0.06, 0.12)
once daily PO)
(P-gp/UGT induction)
Antipsychotics
thioridazine Interaction not studied. Thioridazine may decrease plasma
Expected: concentrations of letermovir.
↓ letermovir Co-administration of letermovir and
thioridazine is not recommended.
(P-gp/UGT induction)
Endothelin antagonists
bosentan Interaction not studied. Bosentan may decrease plasma
Expected: concentrations of letermovir.
↓ letermovir Co-administration of letermovir and
bosentan is not recommended.
(P-gp/UGT induction)
Antivirals
acyclovir‡ ↔ acyclovir No dose adjustment required.
(400 mg single AUC 1.02 (0.87, 1.2)
dose)/ letermovir Cmax 0.82 (0.71, 0.93)
(480 mg daily)
valacyclovir Interaction not studied. No dose adjustment required.
Expected:
↔ valacyclovir
Herbal products
St. John’s wort Interaction not studied. St. John’s wort may decrease plasma
(Hypericum Expected: concentrations of letermovir.
perforatum) ↓ letermovir Co-administration of letermovir and St.
John’s wort is contraindicated.
(P-gp/UGT induction)
HIV medicinal products
efavirenz Interaction not studied. Efavirenz may decrease plasma
Expected: concentrations of letermovir.
↓ letermovir Co-administration of letermovir and
(P-gp/UGT induction) efavirenz is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thioridazine (HOS-086281) valacyclovir (HOS-139811) efavirenz (HOS-087947) bosentan (HOS-086291) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 02b206146672c9c4b512f416bde0babb4730b9e036da24bdcb29f044274b2645 · Zeichen 15644–17913 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 76–77
HOS-139944 · Präparat HOS-098408
76
Concomitant Effect on concentration† Recommendations concerning co-
medicinal product mean ratio (90% confidence administration with letermovir
interval) for AUC, Cmax
(likely mechanism of action)
Antivirals
acyclovir‡ ↔ acyclovir No dose adjustment required.
(400 mg single AUC 1.02 (0.87, 1.2)
dose)/ letermovir Cmax 0.82 (0.71, 0.93)
(480 mg daily)
valacyclovir Interaction not studied. No dose adjustment required.
Expected:
↔ valacyclovir
Herbal products
St. John’s wort Interaction not studied. St. John’s wort may decrease plasma
(Hypericum Expected: concentrations of letermovir.
perforatum) ↓ letermovir Co-administration of letermovir and St.
John’s wort is contraindicated.
(P-gp/UGT induction)
HIV medicinal products
efavirenz Interaction not studied. Efavirenz may decrease plasma
Expected: concentrations of letermovir.
↓ letermovir Co-administration of letermovir and
(P-gp/UGT induction) efavirenz is not recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): valacyclovir (HOS-139811) efavirenz (HOS-087947) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage bac83f7e198e58cee9aef8d163d01669631b97caf31cddd1a11e0d287341c717 · Zeichen 16486–17940 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-141162 · Präparat HOS-098610
Due to the tenofovir disoproxil component of doravirine/lamivudine/tenofovir disoproxil, use of the
product should be avoided with concurrent or recent use of nephrotoxic medicinal products. Some
examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir,
aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cidofovir (HOS-110482) valganciclovir (HOS-085195) valacyclovir (HOS-139811) ganciclovir (HOS-085194) gentamicin (HOS-091173) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage 7a524ecec354aa02b3a620747d8326b100b9c8dfa01e256a1e4bf899ab8122e7 · Zeichen 3065–3455 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.